Identification of lethal inhibitors and inhibitor combinations for mono-driver versus multi-driver triple-negative breast cancer cells
GC Ku, AG Chapdelaine, MK Ayrapetov, G Sun - Cancers, 2022 - mdpi.com
Simple Summary Triple-negative breast cancers lack estrogen and progesterone receptors
and HER2. They lack effective targeted therapies and tend to be more aggressive, with the …
and HER2. They lack effective targeted therapies and tend to be more aggressive, with the …
[HTML][HTML] The power and the promise of synthetic lethality for clinical application in cancer treatment
QW Liu, ZW Yang, QH Tang, WE Wang, DS Chu… - Biomedicine & …, 2024 - Elsevier
Synthetic lethality is a phenomenon wherein the simultaneous deficiency of two or more
genes results in cell death, while the deficiency of any individual gene does not lead to cell …
genes results in cell death, while the deficiency of any individual gene does not lead to cell …
Synthetic lethality prediction in DNA damage repair, chromatin remodeling and the cell cycle using multi-omics data from cell lines and patients.
M Markowska, MA Budzinska, A Coenen-Stass… - Scientific Reports, 2023 - nature.com
Discovering synthetic lethal (SL) gene partners of cancer genes is an important step in
developing cancer therapies. However, identification of SL interactions is challenging, due …
developing cancer therapies. However, identification of SL interactions is challenging, due …
[HTML][HTML] Complementary CRISPR genome-wide genetic screens in PARP10-knockout and overexpressing cells identify synthetic interactions for PARP10-mediated …
JB Khatib, EM Schleicher, LM Jackson, A Dhoonmoon… - Oncotarget, 2022 - ncbi.nlm.nih.gov
PARP10 is a mono-ADP-ribosyltransferase with multiple cellular functions, including
proliferation, apoptosis, metabolism and DNA repair. PARP10 is overexpressed in a …
proliferation, apoptosis, metabolism and DNA repair. PARP10 is overexpressed in a …
DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions
T Chen, S Tongpeng, Z Lu, W Topatana… - Aging and …, 2022 - Wiley Online Library
DNA molecules are subject to various lesions that can be detrimental to the cells. DNA
damage response (DDR) pathways encompass a variety of mechanisms that cells employ in …
damage response (DDR) pathways encompass a variety of mechanisms that cells employ in …
Bourgeoning cancer targets
P Kriplani - Recent Patents on Anti-Cancer Drug Discovery, 2023 - ingentaconnect.com
Identifying cancer genomes has provided acuity into somatically altered genes athwart
tumors, transformed our understanding of biology, and helped us design therapeutic …
tumors, transformed our understanding of biology, and helped us design therapeutic …
The Capacity of Drug-Metabolising Enzymes in Modulating the Therapeutic Efficacy of Drugs to Treat Rhabdomyosarcoma
Simple Summary Rhabdomyosarcoma is a rare type of childhood cancer. Current treatment
options include surgery, radiotherapy, and chemotherapy. Survival chances for RMS …
options include surgery, radiotherapy, and chemotherapy. Survival chances for RMS …
Discovery of thiophen-2-ylmethylene bis-dimedone derivatives as novel WRN inhibitors for treating cancers with microsatellite instability
H Yang, M Kang, S Jang, SY Baek, J Kim… - Bioorganic & Medicinal …, 2024 - Elsevier
Microsatellite instability (MSI) is a hypermutable condition caused by DNA mismatch repair
system defects, contributing to the development of various cancer types. Recent research …
system defects, contributing to the development of various cancer types. Recent research …
ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications
Background Gastroesophageal junction (GEJ) adenocarcinoma is a rare cancer associated
with poor prognosis. The genetic factors conferring predisposition to GEJ adenocarcinoma …
with poor prognosis. The genetic factors conferring predisposition to GEJ adenocarcinoma …
Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives
H Ndlovu, IO Lawal, KMG Mokoala… - International Journal of …, 2024 - mdpi.com
Breast cancer is the most frequently diagnosed cancer and leading cause of cancer-related
deaths worldwide. Timely decision-making that enables implementation of the most …
deaths worldwide. Timely decision-making that enables implementation of the most …